Compare · AVTR vs OMIC
AVTR vs OMIC
Side-by-side comparison of Avantor Inc. (AVTR) and Singular Genomics Systems Inc. (OMIC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and OMIC operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.50B, about 15.4x OMIC ($487.8M).
- AVTR has hit the wire 3 times in the past 4 weeks while OMIC has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 5 for OMIC).
- Company
- Avantor Inc.
- Singular Genomics Systems Inc.
- Price
- $11.03+0.36%
- $19.98+0.35%
- Market cap
- $7.50B
- $487.8M
- 1M return
- +17.91%
- -
- 1Y return
- -15.32%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R